Innate Pharma S.A. ( (IPHYF) ) has released its Q2 earnings. Here is a breakdown of the information Innate Pharma S.A. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Innate Pharma S.A. is a clinical-stage biotechnology company focused on developing immunotherapy treatments against cancer, leveraging the innate immune system through monoclonal antibodies, NK Cell Engagers, and antibody-drug conjugates. Based in Marseille, France, it is publicly traded on Euronext Paris and Nasdaq.
In its latest earnings report for the first half of 2025, Innate Pharma reported a net loss of €21.3 million, a decrease from the €24.8 million loss in the same period of 2024. The company’s cash, cash equivalents, and current and non-current financial assets stood at €70.4 million as of June 30, 2025.
Key financial highlights include operational revenues of €4.9 million, a significant drop from €12.3 million in the first half of 2024, primarily due to reduced collaboration and license agreement revenues. Operational expenses decreased to €30.3 million, with R&D expenses notably reduced by €8.6 million due to the phasing of clinical studies and the completion of certain preclinical studies.
The company reported a net financial gain of €4.1 million, up from €1.5 million in the previous year, driven by favorable currency exchange variations. Despite the reduction in operational revenues, the company continues to focus on its strategic collaborations with major pharmaceutical companies like AstraZeneca and Sanofi.
Looking ahead, Innate Pharma remains committed to advancing its pipeline and anticipates further losses until its drug candidates can generate significant revenues. The company’s future activities will depend on the success of its R&D efforts, market acceptance of its drug candidates, and securing additional funding at opportune moments.